PET/CT with 18F-fluorodeoxyglucose and 11C-methionine after autologous stem cell transplantation in multiple myeloma patients
- 作者: Solovev M1, Mendeleeva L1, Firsova M1, Aslanidi I2, Mukhortova O2, Savchenko V1
-
隶属关系:
- National Research Center for Hematology
- Bakoulev Scientific Center for Cardiovascular Surgery
- 期: 卷 91, 编号 7 (2019)
- 页面: 75-82
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33619
- DOI: https://doi.org/10.26442/00403660.2019.07.000328
- ID: 33619
如何引用文章
全文:
详细
作者简介
M Solovev
National Research Center for Hematology
Email: maxsolovej@mail.ru
врач-гематолог, зав. отд-нием интенсивной высокодозной химиотерапии парапротеинемических гемобластозов ФГБУ «НМИЦ гематологии» Минздрава России; ORCID: 0000-0002-7944-6202 Moscow, Russia
L Mendeleeva
National Research Center for Hematologyд.м.н., проф., зам. генерального директора по научной работе и инновациям ФГБУ «НМИЦ гематологии» Минздрава России; ORCID: 0000-0002-4966-8146 Moscow, Russia
M Firsova
National Research Center for Hematologyн.с. отд-ния интенсивной высокодозной химиотерапии парапротеинемических гемобластозов ФГБУ «НМИЦ гематологии» Минздрава России; ORCID: 0000-0003-4142-171X Moscow, Russia
I Aslanidi
Bakoulev Scientific Center for Cardiovascular Surgeryд.м.н., зав. отд. ядерной диагностики с ПЭТ-центром ФГБУ «НМИЦ сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России; ORCID: 0000-0001-6386-2378 Moscow, Russia
O Mukhortova
Bakoulev Scientific Center for Cardiovascular Surgeryд.м.н., с.н.с. отд. ядерной диагностики с ПЭТ-центром ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России; ORCID: 0000-0002-7716-5896 Moscow, Russia
V Savchenko
National Research Center for Hematologyакад. РАН, д.м.н., проф., генеральный директор ФГБУ «НМИЦ гематологии» Минздрава России; ORCID: 0000-0001-8188-5557 Moscow, Russia
参考
- Лучинин А.С., Семочкин С.В., Минаева Н.В., Поздеев Н.М., Парамонов И.В. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50-6. doi: 10.17650/1818-8346-2017-12-3-50-56
- Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Множественная миелома: 7 лет таргетной терапии и ее результаты в Новосибирске. Клиническая онкогематология. 2015;8(3):267-73. http://bloodjournal.ru/wp-content/uploads/2015/11/4-Stra nitsy-iz-ONCO_3_20151-4.pdf
- Dimopoulos M.A, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan G.J, Davies F.E, Sonneveld P, Schey S.A, Zweegman S, Hansson M, Weisel K, Mateos M.V, Facon T, Miguel J.F. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573-85. doi: 10.1038/leu.2014.60
- Dytfeld D, Jasielec J, Griffith K.A, Lebovic D, Vesole D.H, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki D.E, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak A.J. Carfilzomib, lenalidomide, and low - dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014; 99(9):162-4. doi: 10.3324/haematol.2014.110395
- Gay F, Oliva S, Petrucci M.T, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella A.M, Omedé P, Liberati A.M, Troia R, Cafro A.M, Malfitano A, Falcone A.P, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-34. doi: 10.1038/leu.2016.381
- Lonial S, Vij R, Harousseau J.L, Facon T, Moreau P, Mazumder A, Kaufman J.L, Leleu X, Tsao L.C, Westland C, Singhal A.K, Jagannath S. Elotuzumab in combination with lenalidomide and low - dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649
- Lonial S, Weiss B.M, Usmani S.Z, Singhal S, Chari A, Bahlis N.J, Belch A, Krishnan A, Vescio R.A, Mateos M.V, Mazumder A, Orlowski R.Z, Sutherland H.J, Bladé J, Scott E.C, Oriol A, Berdeja J, Gharibo M, Stevens D.A, Le Blanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson P.G, Lisby S, Feng H, Uhlar C.M, Khan I, Ahmadi T, Voorhees P.M. Daratumumab monotherapy in patients with treatment - refractory multiple myeloma (SIRIUS): an open - label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4
- Moreau P, San Miguel J, Sonneveld P, Mateos M.V, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos M.A, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. doi: 10.1093/ annonc/mdx096
- Richardson P.G, Hofmeister C.C, Raje N.S, Siegel D.S, Lonial S, Laubach J, Efebera Y.A, Vesole D.H, Nooka A.K, Rosenblatt J, Doss D, Zaki M.H, Bensmaine A, Herring J, Li Y, Watkins L, Chen M.S, Anderson K.C. Pomalidomide, bortezomib and low - dose dexamethasone in lenalidomide - refractory and proteasome inhibitor - exposed myeloma. Leukemia. 2017;31(12):2695-701. doi: 10.1038/leu.2017.173
- Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa A-M.M, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien M-L.L, Facon T, Avet-Loiseau H, Attal M. Front - line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164
- Usmani S.Z, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017;92(8):E146-E152. doi: 10.1002/ajh.24781
- Kaatsch P, Spix C, Hentschel S, Katalinic A, Luttmann S, Stegmaier C. Cancer in Germany. 2009/2010. Berlin, 2014:16-18.
- Myeloma Statistics American Cancer Society - Cancer Facts &. Accessed May 15, 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma
- Mendeleeva L.P. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(1):5408. Accessed March 20, 2019. http://www.bloodjournal.org/content/130/Suppl_1/5408?sso-checked= true
- Городецкий В.Р., Пробатова Н.А., Васильев В.И., Мухортова О.В., Асланиди И.П., Сидорова Ю.В., Рыжикова Н.В., Раденска-Лоповок С.Г., Егорова О.Н. Подкожная панникулитоподобная Т-клеточная лимфома. Собственный опыт в диагностике и лечении. Терапевтический архив. 2016;88(7):49-55. doi: 10.17116/terarkh201688749-55
- Демина Е.А., Леонтьева А.А., Тумян Г.С., Рябухина Ю.Е., Медведовская Е.Г., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Кокосадзе Н.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А. Значение позитронно - эмиссионной томографии в оптимизации терапии распространенных стадий лимфомы Ходжкина с использованием интенсивной программы ЕАСОРР-14. Клиническая онкогематология. 2017;10(2):150-7. doi: 10.21320/2500-2139-2017-10-2-150-157
- Kostakoglu L, Cheson B.D. State - of - the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. Front Oncol. 2013;3(212). doi: 10.3389/fonc.2013.00212
- Meignan M, Hutchings M, Schwartz L.H. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist. 2015;20(8):890-5. doi: 10.1634/theoncologist.2015-0036
- Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017;18(2):445. doi: 10.3390/ijms18020445
- Mukhortova О, Aslanidis I, Katunina T, Rumjantzev A, Silchenkov A, Solovev M, Mendeleeva L. PET/CT with 18F-FDG and 11C-methionine for assessment of remission status after autologous stem cell transplantation in multiple myeloma patients. Eur J Nucl Med Mol Imaging. 2017;44:383-4.
- Usmani S.Z, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro - deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-23. doi: 10.1182/blood-2012-08-451690
- Rajkumar S.V, Dimopoulos M.A, Palumbo A, Blade J, Merlini G, Mateos M.V, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, Le Leu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson S.Y, Caers J, Usmani S.Z, Lahuerta J.J, Johnsen H.E, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle R.A, Anderson K.C, Durie B.G, Miguel J.F. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-48. doi: 10.1016/S1470-2045(14)70442-5
- Bartel T.B, Haessler J, Brown T.L, Shaughnessy J.D. Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76. doi: 10.1182/blood-2009-03-213280
- Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clin Nucl Med. 2015;40(4):303-8. doi: 10.1097/RLU.0000000000000696
- Haznedar R, Akı S.Z, Akdemir O.U, Ozkurt Z.N, Ceneli O, Yağcı M, Sucak G.T, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046-53. doi: 10.1007/s00259-011-1738-8
- Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up - front autologous transplantation. Blood. 2011;118(23):5989-95. doi: 10.1182/blood-2011-06-361386
- Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani S.Z, Vesole D.H, San-Miguel J, Kumar S.K, Richardson P.G, Mikhael J.R, da Costa F.L, Dimopoulos M.A, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski R.Z, Chng W.J, Einsele H, Lonial S, Barlogie B, Anderson K.C, Rajkumar S.V, Durie B.G.M, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):206-17. doi: 10.1016/S1470-2045(17)30189-4
- Lapa C, Garcia-Velloso M.J, Lückerath K, Samnick S, Schreder M, Otero P.R, Schmid J-S, Herrmann K, Knop S, Buck A.K, Einsele H, San-Miguel J, Kortüm K.M. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017;7(11):2956-64. doi: 10.7150/thno.20491
- Kumar S, Paiva B, Anderson K.C, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos M.V, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng W.J, Usmani S.Z, Zamagni E, Shimizu K, Jagannath S, Johnsen H.E, Terpos E, Reiman A, Kyle R.A, Sonneveld P, Richardson P.G, Mc Carthy P, Ludwig H, Chen W, Cavo M, Harousseau J.L, Lentzsch S2, Hillengass J1, Palumbo A, Orfao A, Rajkumar S.V, Miguel J.S. Avet-Loiseau H30International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328-46. doi: 10.1016/S1470-2045(16)3020 6-6
- Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355-63. doi: 10.3109/ 10428194.2012.740559
- Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography - computed tomography, magnetic resonance imaging and whole - body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-5.
- Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck A.K. Targeting paraprotein biosynthesis for non - invasive characterization of myeloma biology. PLoS One. 2013;8(12):84840. https://opus.bibliothek.uni-wuerzburg.de/opus4 wuerzburg/frontdoor/deliver/index/doc Id/11131/file/ 024_Lueckerath_PLoS.pdf